Chiesi Farmaceutici has bought Atopix Therapeutics for its pipeline of asthma treatments. The buyout gives Chiesi an orally administered CRTh2 antagonist that Atopix is testing in a Phase II trial ...

the company is sponsoring two symposia focused on improving patient quality of life in asthma and COPD and will present during a poster session findings from the TANGO trial, where Chiesi is ...

and use of digital tools by asthma and COPD patients. According to Aptar and Chiesi, respiratory illnesses represent an enormous burden on healthcare systems in Europe, with an annual cost of ...

The SMC approval brings much-needed boost to asthma sufferers across Scotland The SMC approval brings much-needed boost to asthma sufferers across Scotland Chiesi has announced that the Scottish ...

Our study revealed that air pollution, lack of green space and areas built primarily from concrete and asphalt were key ...

The episode, which was paid for and presented by Chiesi, goes on to discuss how the development of carbon-minimal inhalers could reduce the impact of asthma drugs on the environment. Respiratory ...

Parma Italy, Boston MA and Dublin, Ireland, January 8, 2023 Chiesi Farmaceutici S.p.A. (“Chiesi”), an international, research-focused biopharmaceuticals and healthcare group, and Amryt Pharma ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations ...